Lilly Q4 revenue up 43% to $19.3B; EPS $7.39 (+51%); FY2026 guidance $80-83B

ELI LILLY & Co

2025-FY EPS reported $22.95 revenue$65,179,000,000

Q4 revenue $19.3B (+43% YoY); reported EPS $7.39 (+51%); non-GAAP EPS $7.54 (+42%), both incl. $0.52 acquired IPR&D.
FY2026 guidance: revenue $80-83B; non-GAAP EPS $33.50-$35.00.
FDA approved Kwikpen for tirzepatide; filed orforglipron for obesity in US, Japan, and EU.
Positive Phase 3 results for Taltz+Zepbound combo in psoriatic arthritis and retatrutide for knee osteoarthritis.
Agreement with U.S. government to expand access to obesity medicines for millions of Americans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.